PA
REGN icon

Pinnacle Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Pinnacle Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-900
Closed -$338K – 712
2019
Q4 		$338K Buy
+900
New +$303K 0.01% 590

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pinnacle Associates's REGN Position: Q1 2026 in Review

Pinnacle Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 1.5% in Q1 2026, selling an estimated $941K and leaving 82,512 shares worth $63.8M. The position accounts for 0.82% of the portfolio, ranked #23.

Pinnacle Associates first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $190M in Q3 2013. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Pinnacle Associates held 82,512 shares of Regeneron Pharmaceuticals worth $63.8M as of Q1 2026.
  • Pinnacle Associates sold 1,229 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $941K.
  • Regeneron Pharmaceuticals made up 0.82% of Pinnacle Associates's portfolio in Q1 2026, its #23 holding.
  • Pinnacle Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Pinnacle Associates's Regeneron Pharmaceuticals position peaked at $190M in Q3 2013.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.